InflaRx N.V.
- Last sale
- Nov 12, 2026 · +5.53%
- Market cap
- $89.64M
- 72.29M shares
- Filings
- 291
FY 2025−82.3% FY25 yoy
FY 2025N/M FY25 yoy
FY 2023N/M FY23 yoy
Q2 2023derived
—FY 2025N/M FY25 yoy
FY 2025−12.8% FY25 yoy
- $89.64M
- —
- —
- —
- —
- —
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | €29,331 | reported | |
| FY 2024 | 2024-12-31 | €165,789 | reported | |
| FY 2023 | 2023-12-31 | €63,089 | reported |
Segments
Geography
LineFY2022ShareChange
Germany€29.26M587%+1,609.2%
United States€200.00K4.0%−8.7%
Germany———
United States———
Total€4.99M
Pharmaceutical preparations
InflaRx N.V. is the 297th largest of the 552 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
PLYXPolaryx Therapeutics, Inc.———$94.2MHURATuHURA Biosciences, Inc.$0.0——$94.0MANIXAnixa Biosciences Inc———$93.2MPMVPPMV Pharmaceuticals, Inc.———$92.2MRACCResearch Alliance Corp III———$91.9MGNLXGenelux Corp$8.0K0.0%401,812.5%$91.6MNKTXNkarta, Inc.$0.0——$90.7M
IFRXInflaRx N.V. (this company)———$89.6M
KZIAKazia Therapeutics Ltd———$89.6MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
InflaRx N.V. · CIK 1708688 · Engraved from SEC EDGAR